Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Resmed ( (RMD) ).
On July 31, 2025, Resmed announced a quarterly cash dividend of $0.60 per share, reflecting a 13% increase, with payment scheduled for September 18, 2025. The company also reported a strong financial performance for the fourth quarter and the full fiscal year 2025, with a 10% revenue growth and a 19% increase in operating profit. These results highlight Resmed’s robust market position and the effectiveness of its digital health ecosystem, which continues to drive demand and innovation in sleep and breathing health solutions.
The most recent analyst rating on (RMD) stock is a Buy with a $290.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.
Spark’s Take on RMD Stock
According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.
ResMed’s overall strong financial performance and positive earnings call sentiment are the most significant factors driving its stock score. While technical analysis shows bullish momentum, caution is advised as the stock approaches overbought levels. The valuation is moderate, reflecting a fair market price.
To see Spark’s full report on RMD stock, click here.
More about Resmed
Resmed Inc. operates in the healthcare industry, focusing on sleep and breathing health devices and digital health solutions. The company is known for its market-leading products that empower individuals to manage their health at home.
Average Trading Volume: 873,361
Technical Sentiment Signal: Buy
Current Market Cap: $40.72B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.